Please use this identifier to cite or link to this item:
Title: Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study
Authors: Chen, C.L.
Young, S.H.
Gan, H.H.
Singh, R.
Lao, A.Y.
Baroque, A.C.
Chang, H.M.
Hiyadan, J.H.
Chua, C.L.
Advincula, J.M.
Muengtaweepongsa, S.
Chan, B.P.
de Silva, H.A.
Towanabut, S.
Suwanwela, N.C.
Poungvarin, N.
Chankrachang, S.
Wong, K.S.
Eow, G.B.
Navarro, J.C.
Venketasubramanian, N.
Lee, C.F.
Bousser, M.G.
CHIMES Study Investigators
Issue Date: 2013
Publisher: Lippincott Williams and Wilkins
Citation: Stroke. 2013; 44(8): 2093-100 [Epub 2013 Jun 18.]
Abstract: BACKGROUND AND PURPOSE: Previous clinical studies suggested benefit for post stroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window. METHODS: This multicenter, double-blind, placebo-controlled trial randomized 1100 patients with a National Institutes of Health Stroke Scale score 6 to 14, within 72 hours of onset, to trial medications for 3 months. The primary outcome was a shift in the modified Rankin Scale. Secondary outcomes were modified Rankin Scale dichotomy, National Institutes of Health Stroke Scale improvement, difference in National Institutes of Health Stroke Scale total and motor scores, Barthel index, and mini-mental state examination. Planned subgroup analyses were performed according to age, sex, time to first dose, baseline National Institutes of Health Stroke Scale, presence of cortical signs, and antiplatelet use. RESULTS: The modified Rankin Scale shift analysis-adjusted odds ratio was 1.09 (95% confidence interval, 0.86-1.32). Statistical difference was not detected between the treatment groups for any of the secondary outcomes. Subgroup analyses showed no statistical heterogeneity for the primary outcome; however, a trend toward benefit in the subgroup receiving treatment beyond 48 hours from stroke onset was noted. Serious and nonserious adverse events rates were similar between the 2 groups.CONCLUSIONS:MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. Longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies. CLINICAL TRIAL REGISTRATION: URL: Unique identifier: NCT00554723.
ISSN: 0039-2499 (Print)
1524-4628 (Electronic)
Appears in Collections:Journal/Magazine Articles

Files in This Item:
File Description SizeFormat 
Chen-Stroke-2013-2093.pdf1.28 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.